ArticleFrontiers in endocrinology2026
Neurological manifestations in metabolic dysfunction syndrome are associated with cumulative metabolic burden beyond hyperglycaemia: a translational study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine whether neurological injury in metabolic syndrome (MetS) extends beyond hyperglycaemia-driven neuropathy. Methods: We employed a translational design combining controlled rat models of isolated and combined MetS components with a community-based cross-sectional human study. Preclinically, ten rat models (n = 6 per group) representing various MetS phenotypes were assessed for metabolic parameters and peripheral neurological function. Clinically, 1,176 adults were stratified by glycaemic and MetS status according to International Diabetes Federation (IDF) criteria. Participants underwent anthropometric measurements, fasting biochemistry, peripheral nerve function assessment by electromyography (EMG), and autonomic function evaluation by heart rate variability (HRV) and electrogastrography (EGG). Results: In animal models, hindpaw withdrawal latencies were prolonged and nerve conduction velocity (NCV) was significantly reduced across multiple MetS phenotypes, irrespective of glycaemic status. In humans, the MetS with euglycaemia group exhibited peripheral neuropathy, with reduced nerve amplitudes and slowed NCV (P < 0.05). HRV analysis revealed significant cardiac autonomic dysfunction in the MetS with euglycaemia group, including reductions in the root mean square of successive differences (RMSSD), the standard deviation of normal-to-normal intervals (SDNN), total power (TP), high-frequency (HF) power, and the Poincaré long-axis index (SD2) (all P < 0.05)-deficits that were comparable to or exceeded those in the isolated hyperglycaemia group. Gastrointestinal dysautonomia, however, was prominent only in the MetS with hyperglycaemia subgroup. Interpretation: Both peripheral and autonomic neuropathies in MetS are associated with cumulative metabolic burden rather than hyperglycaemia alone, with organ-specific susceptibility patterns. These findings challenge a purely glucocentric view of MetS-related neural injury and support comprehensive risk-factor management in all MetS patients, irrespective of glycaemic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.